Mineralys Therapeutics, Inc. (MLYS) Tops Q3 EPS by 19c

Mineralys Therapeutics, Inc. (NASDAQ: MLYS) reported Q3 EPS of ($0.57), $0.19 better than the analyst estimate of ($0.76).

For earnings history and earnings-related data on Mineralys Therapeutics, Inc. (MLYS) click here.

You May Also Be Interested In

• Walmart (WMT) PT Lowered to $130 at UBS on Investment Narrative's Competing Dynamics
• Intchains Group Ltd (ICG) PT Lowered to $2 at Benchmark Following 1H Results
• Bernstein SocGen on Meta Platforms Inc. (META): 'Risk-reward remains attractive'